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A B S T R A C T
Background
This is an update of a review first published in The Cochrane Library in Issue 3, 2013. Cancer-related pain places a heavy burden on
public health with related high expenditure. Severe pain is associated with a decreased quality of life in patients with cancer. A significant
proportion of patients with cancer-related pain are under-treated. There is a need for more effective control of cancer-related pain.
Spinal cord stimulation (SCS) may have a role in pain management. The effectiveness and safety of SCS for patients with cancer-related
pain is currently unknown.
Objectives
This systematic review evaluated the effectiveness of SCS for cancer-related pain compared with standard care using conventional
analgesic medication. We also appraised risk and potential adverse events associated with the use of SCS.
Search methods
This is an update of a review first published in The Cochrane Library in Issue 3, 2013. The search strategy for the update was the same
as in the original review. We searched the following bibliographic databases in order to identify relevant studies: the Cochrane Central
Register of Controlled Trials (CENTRAL) in The Cochrane Library; MEDLINE; EMBASE; and CBM (Chinese Biomedical Database)
in October 2014. We also handsearched relevant journals. There were no language restrictions.
Selection criteria
We planned to include randomised controlled trials (RCTs) that directly compared SCS with other interventions with regards to the
effectiveness of pain management. We also planned to include cross-over trials that compared SCS with another treatment. We planned
to identify non-randomised controlled trials but these would only be included if no RCTs could be found.
Data collection and analysis
The literature search for the update of this review found 121 potentially eligible articles. The initial search strategy yielded 430 articles.
By scrutinising titles and abstracts, we found 412 articles irrelevant to the analytical purpose of this systematic review due to different
scopes of diseases or different methods of intervention (intrathecal infusion system; oral medication) or aims other than pain control
(spinal cord function monitoring, bladder function restoration or amelioration of organ metabolism). The remaining 18 trials were
reviewed as full manuscripts. No RCTs were identified. Fourteen sporadic case reports and review articles were excluded and four before-
and-after case series studies (92 participants) were included. Two review authors independently selected the studies to be included in the
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review according to the prespecified eligibility criteria. A checklist for methodological quality of non-randomised controlled trials was
used (STROBE checklist) and all review authors discussed and agreed on the inclusion of trials and the results of the quality assessment.
Main results
No new studies were identified for inclusion in this update of the review. Four before-and-after case series studies (a total of 92
participants) met our criteria for inclusion in the previous version of the review. All included trials adopted a visual analogue scale
(VAS) to evaluate pain relief. Heterogeneity existed in terms of baseline characteristics, electrode and stimulator parameters, level of
implantation and route of implantation; each trial reported data differently. In two trials, pain relief was achieved in 76% (48/63) of
participants at the end of the follow-up period. In the third trial, pre-procedure VAS was 6 to 9 (mean 7.43 ); the one-month post-
implant VAS was 2 to 4 (mean 3.07); the 12-month post-implant VAS was 1 to 3 (mean 2.67). In the fourth trial, the pre-procedure
VAS was 6 to 9 (mean 7.07); 1 to 4 (mean 2.67) at one-month; 1 to 4 (mean 1.87) at 12 months. Analgesic use was largely reduced.
The main adverse events were infection of sites of implantation, cerebrospinal fluid (CSF) leakage, pain at the sites of electrodes,
dislodgement of the electrodes, and system failure; however, the incidence in participants with cancer could not be calculated. Since all
trials were small, non-randomised controlled trials, they carried high or unclear risk of all types of bias.
Authors’ conclusions
Since the first publication of this review, no new studies were identified. Current evidence is insufficient to establish the role of SCS in
treating refractory cancer-related pain. Future randomised studies should focus on the implantation of SCS in participants with cancer-
related pain.
P L A I N L A N G U A G E S U M M A R Y
Spinal cord stimulation for cancer pain
People with cancer often experience pain. Cancer pain or cancer-related pain is one of the worst factors for these patients. This type of
pain tends to get worse as the cancer progresses. Despite better analgesics (pain killers) and techniques, cancer pain is still a problem
for many people.
Traditionally, cancer pain was controlled by drugs. When these drugs do not work, other ways of reducing pain can be used, such as
neuromodulation (electrical stimulation of the nerves). Spinal cord stimulation is the most common method of neuromodulation.
Spinal cord stimulation (SCS) involves putting electrodes on the spinal cord to control pain. The electrodes deliver impulses that may
reduce pain. The technique is reversible and minimally invasive. SCS appears to have very few side effects, e.g. tiredness, compared
to drugs used for pain relief. This technique has been widely used in non-cancer patients, yet the role of SCS for cancer pain is still
unclear.
In the original review, we intended to evaluate how well SCS worked for cancer pain, compared with standard care (e.g. drugs). We
also planned to look at harm and side effects of the treatment. To update this review, in October 2014 we looked for clinical trials that
used SCS to treat cancer pain. We found no randomised controlled trials and four before-and-after case series studies (a total of 92
participants with cancer). All studies were small and of low quality.
SCS participants used fewer drugs than standard treatment group. The main side effects were infection and pain at the sites of electrodes,
cerebrospinal fluid (CSF) leakage, dislodged electrodes, and system failure. However, we could not tell which side effects occurred more
frequently in cancer patients compared to non-cancer patients.
There is not enough good quality evidence to know whether SCS is better than drugs to relieve cancer pain. More trials comparing
SCS with other ways of relieving pain are needed.
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B A C K G R O U N D
This is an update of the review titled ’Spinal cord stimulation
for cancer-related pain in adults’, first published in the Cochrane
Database of Systematic Reviews in Issue 3, 2013.
Description of the condition
World-wide, cancer-related pain has increasingly become a heavy
burden on public health with related high expenditure. It has been
estimated that world-wide nearly sevenmillion people suffer mod-
erate-to-severe cancer-related pain each year caused directly by
cancer or by cancer treatment. An epidemiological study revealed
that some 15% of these patients fail to achieve acceptable pain
relief with conventional management (Running 2011; Yakovlev
2008). Severe pain is associated with a decreased quality of life and
unwanted life events such as depression, anxiety and even suicide.
Conventional treatment is based on the World Health Organiza-
tion (WHO) guidelines for cancer pain management which con-
sists of a three-step ladder: (1) non-steroidal anti-inflammatory
drugs (NSAIDs), aspirin, and acetaminophen for mild-to-mod-
erate levels of cancer pain; (2) weak opioids for mild-to-moder-
ate pain that does not respond to NSAIDs alone; and (3) strong
opioids for moderate-to-severe levels of cancer pain (Schug 1990).
Adjuvant medications, such as antiepileptics and tricyclic antide-
pressants, can also be added at any step of the ladder for opti-
mal pain relief. Reduced pain intensity and standardised protocols
have been used globally for improving cancer pain management.
When this approach fails (10% of patients), interventional pain
management has been proposed for this groupwith refractory pain
(Miguel 2000).
Among all the diversified procedures of interventional manage-
ment approaches for pain control, alternative strategies are needed
such as (1) neuroaxial analgesia (spinal, epidural); (2) neurostimu-
lation; (3) neurolysis (sympathetic blockades with phenol or alco-
hol); and (4) thermal neurolysis (radiofrequency) (Slavik 2004).
The most commonly used forms of neuromodulation are (1) neu-
rostimulation: the electric stimulation of peripheral nerves, the
spinal cord (spinal cord stimulation (SCS)), and brain (deep brain
stimulation); (2) intrathecal drug delivery system bymeans of pro-
grammed infusion pumps. To date, different techniques of neuro-
modulation are among themore frequently used types of interven-
tional procedures in the treatment of non-cancer pain (Isagulian
2008).
Although the aetiology of cancer pain is not yet fully understood,
altered peripheral nociception (the ability to feel pain) and cen-
tral sensitisation involving the level of SCS have pivotal roles in
its pathogenesis (Schmidt 2010). Within the cancer microenvi-
ronment, cancer and immune cells produce and secrete mediators
that activate and sensitise primary afferent nociceptors. In addi-
tion, neuropathic mechanisms are also prevalent and cancer pain
is often regarded as a mixed-pain mechanism (Ro 2005).
As our understanding of the peripheral and central mechanisms
that underlie cancer pain improves, targeted analgesics for the pa-
tient with cancer will likely follow, especially in relation to the
spinal cord (Boswell 2010; Christo 2008). Thus, when pharma-
cotherapy (such as opioids and potent COX-2 inhibitors) for se-
vere and intractable cancer-related pain are ineffective, interven-
tional management approaches have received considerable atten-
tion in an attempt to provide pain relief for patients with cancer
pain. These offer important additional approaches to the WHO
analgesic ladder to control cancer-related pain. Neurostimulation
in particular has been recognised in non-cancer pain as having
the potential for long-term effectiveness with minimal side effects
observed clinically. Currently, the evidence that neurostimulation
is effective for the long-term treatment of non-malignant painful
conditions such as angina, limb ischaemia, and lower back pain has
been established (Kemler 2010; Klomp 2009; North 2008; Taylor
2009). Since chronic cancer pain has some features in common
in its pathogenesis with non-malignant pain, systematic reviews,
sporadic case series and cohorts of observational studies have re-
ported a marked reduction of pain intensity using this approach
(Mailis-Gagnon 2004; Ubbink 2005; Yakovlev 2008).
SCS can provide long-term relief in managing patients with failed
back surgery syndrome and the level of evidence recommendation
is Level II-1 or II-2 (Michael 2009). SCS has also been recorded
to be effective in reducing the chronic neuropathic pain of com-
plex regional pain syndrome (CRPS) type I (Simpson 2009); this
evidence has helped to establish the potential role of SCS in treat-
ing patients with cancer-related pain. However, the effectiveness
and relative safety of SCS for cancer pain has not been adequately
established (Engle 2013). Therefore, in this systematic review, we
intended to provide scientific evidence as to the efficacy of SCS;
the safety of patients receiving SCS; and to identify which patients
are most likely to benefit.
Description of the intervention
SCS is achieved by placing electrodes in the epidural space on
the dorsal surface of the spinal cord. The electrodes can be placed
either by using an open procedure in which the dura is exposed
(surgical laminotomy), or a closed procedure via epidural needles.
The electrodes are connected to an impulse generator that is also
inserted under the skin. The impulse generator is programmed
using an external device to deliver impulses continuously or in
preset patterns throughout a 24-hour period. The technique is
reversible and minimally invasive (in contrast to nerve ablation)
(Costantini 2005); and appears to result in no adverse effects such
as sedation or lethargy, commonly associated with centrally-acting
analgesic drugs.
How the intervention might work
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The basic scientific background of SCS is based on the gate control
theory of Melzack and Wall (Stephen 2005). It has been demon-
strated inmultiple studies that dorsal hornneuronal activity caused
by peripheral noxious stimuli could be inhibited by concomi-
tant stimulation of the dorsal columns. Various other mechanisms
which may play a significant role in the mechanism of action of
SCS include the suppressive effect of SCS on tactile allodynia (pain
produced from a stimulus that would not normally produce pain),
increased dorsal horn inhibitory action of gamma-aminobutyric
acid (GABA), prevention or abolition of peripheral ischaemia, and
effects on human brain activity (Stojanovic 2002). Thus, the use
of SCS to treat cancer-related pain can be mechanism-based and
tailored to the needs of the individual patient. Although opioids
remain themainstay of analgesia for cancer pain (IASP 2008), SCS
can be used in addition to, or instead of, conventional approaches.
The mixed-pain mechanisms that can result from cancer suggest
that multi-modal approaches are likely to result in better outcomes
for patients (Herr 2004).
Why it is important to do this review
Despite a few case series and expert recommendations of the po-
tential significance of SCS for cancer-related pain, few cohort stud-
ies and fewer randomised controlled trials (RCTs) have been con-
ducted to establish the efficacy of this approach in cancer pain. It
is important to identify this in a systematic review so that it can
help inform the need for further RCTs in this area and ultimately
clinical practice.
O B J E C T I V E S
This systematic review evaluated the effectiveness of SCS for can-
cer-related pain compared with standard care using conventional
analgesic medication. We also appraised risk and potential adverse
events associated with the use of SCS.
M E T H O D S
Criteria for considering studies for this review
Types of studies
For the purpose of generating high-quality evidence, we planned
to include randomised controlled trials (RCTs) that directly com-
pared spinal cord stimulation (SCS) with other interventions for
pain management. We also intended to include cross-over trials
comparing SCS with another treatment. Non-randomised con-
trolled trials were included as no RCTs were identified.
Types of participants
Adult participants aged between 18 and 80 years old with cancer-
related pain who were eligible for the implantation of SCS and
treated accordingly with this intervention for cancer-related pain
management.
Types of interventions
1. Participants receiving SCS versus participants receiving
conventional medical treatments.
2. Participants receiving SCS plus conventional medical
treatments versus participants receiving conventional medical
treatments only.
3. Participants receiving SCS versus participants receiving
physical therapies or complementary therapies.
4. Participants receiving SCS versus participants receiving
other invasive interventions such as surgery or neuro-ablation
therapies.
Types of outcome measures
Primary outcomes
Effectiveness of pain management:
• at least 50% reduction of pain (visual analogue score (VAS)
as the primary parameter);
• health-related quality of life;
• physical and functional abilities;
• pain-related anxiety and depression.
Secondary outcomes
Adverse events related to SCS, e.g. rate of procedural complications
(bleeding, infection, spinal cord compression etc), incidence of
technical failures and withdrawal rate, incidence of treatment-
related mortality.
Search methods for identification of studies
Electronic searches
For this update we searched the following bibliographic databases
for relevant studies:
• the Cochrane Register of Controlled Trials (CENTRAL) in
The Cochrane Libary (Issue 9, 2014);
• MEDLINE (July 2012 to 6 October 2014);
• EMBASE (July 2012 to 6 October 2014);
• CBM (Chinese Biomedical Database) (from July 2012 to 1
October 2014).
The search strategies used can be found in Appendix 1.
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Searching other resources
We also searched the trials registry of the National Cancer Insti-
tute, theWorldHealthOrganization (WHO) International Clini-
cal Trials Registry Platform (http://apps.who.int/trialsearch/) and
clinicaltrials.gov supported by U.S. National Institutes of Health
for eligible ongoing trials. We searched abstracts of international
conferences related to cancer pain management using the term
’spinal cord stimulation’. We handsearched major international
journals such as Pain,The Clinical Journal of Pain, European Jour-
nal of Pain, and conference articles of internationally renowned
associations of pain such as the International Association for the
Study of Pain (IASP), European Society of Regional Anesthesia &
Pain Therapy (ESRA) and American Pain Society (APS) for pre-
liminary reports of high-quality studies on a week-to-week basis.
We checked reference lists of updated articles of importance. We
also searched international conference proceedings and seminars
for potential studies. There were no language restrictions.
Data collection and analysis
Selection of studies
In the updated and initial search, two review authors (Lihua Peng
and Ke Wei) independently selected the studies to be included in
the review according to the prespecified eligibility criteria. Dis-
agreements were resolved by discussion. If this did not resolve the
disagreement, we consulted a third review author (Michael I Ben-
nett). We based decisions for inclusion or exclusion on the whole
content of the studies if available.
Data extraction and management
One review author (Lihua Peng) extracted data and these were
checked by a second review author (Su Min). Data entry into
Review Manager (RevMan 2014) was also double-checked. We
resolved disagreements concerning data extraction by reaching a
consensus based on the inclusion criteria. Where we could not
resolve disagreements, we consulted a third review author (Michael
I Bennett).
We recorded the following data for each study:
• details of methodology including whether the study was
randomised; and whether the methods of sequence generation,
allocation sequence concealment, and blinding were reported;
• details of the participants including age, gender, and
diagnosis before SCS;
• details of the experimental and control interventions
including the intervention type, name, dosage, and schedules.
Assessment of risk of bias in included studies
Two authors (Ke Wei, Lihua Peng) independently assessed risk
of bias for each study, using the criteria outlined in the Cochrane
Handbook for Systematic Reviews of Interventions (Higgins 2011);
and adapted from those used by the Cochrane Pregnancy and
Childbirth Group, with any disagreements resolved by discussion.
We completed a ’Risk of bias’ table for each included study using
the Risk of bias tool in RevMan (RevMan 2014) (Figure 1; Figure
2).
Figure 1. Risk of bias graph: review authors’ judgements about each risk of bias item presented as
percentages across all included studies.
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Figure 2. Risk of bias summary: review authors’ judgements about each risk of bias item for each included
study.
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We had planned to assess the following for each study:
• random sequence generation (checking for possible
selection bias). We had planned to assess the method used to
generate the allocation sequence as: low risk of bias (any truly
random process, e.g. random number table; computer random
number generator); and unclear risk of bias (method used to
generate sequence not clearly stated). Studies using a non-
random process (e.g. odd or even date of birth; hospital or clinic
record number) would be excluded.
• allocation concealment (checking for possible selection
bias). The method used to conceal allocation to interventions
prior to assignment determines whether intervention allocation
could have been foreseen in advance of, or during, recruitment;
or changed after assignment. We had planned to assess the
methods as: low risk of bias (e.g. telephone or central
randomisation; consecutively numbered sealed opaque
envelopes); unclear risk of bias (method not clearly stated).
Studies that do not conceal allocation (e.g. open list) will be
excluded.
• blinding of outcome assessment (checking for possible
detection bias). We had planned to assess the methods used to
blind study participants and outcome assessors from knowledge
of which intervention a participant received. We had planned to
assess the methods as: low risk of bias (study states that it was
blinded and describes the method used to achieve blinding, e.g.
identical tablets; matched in appearance and smell); unclear risk
of bias (study states that it was blinded but does not provide an
adequate description of how it was achieved). Studies that were
not double-blind would be excluded.
• incomplete outcome data (checking for possible attrition
bias due to the amount, nature and handling of incomplete
outcome data). We had planned to assess the methods used to
deal with incomplete data as: low risk (less than 10% of
participants did not complete the study or used ‘baseline
observation carried forward’ analysis or both); unclear risk of bias
(used ’last observation carried forward’ analysis); high risk of bias
(used ’completer’ analysis).
• Size of study (checking for possible biases confounded by
small size). We had planned to assess studies as being at low risk
of bias (equal to or greater than 200 participants per treatment
arm); unclear risk of bias (50 to 199 participants per treatment
arm); high risk of bias (fewer than 50 participants per treatment
arm).
We had also planned to assess the quality of included studies us-
ing different aspects: adequate allocation concealment; scientific
methods of randomisation and balanced enrolment of participants
between different interventional arms; follow-up of adequate time;
and inclusion of the intention-to-treat (ITT) principle during data
analysis. As SCS is a minimally invasive yet prominent interven-
tion against cancer pain, we assessed blinding of participants to
genuine stimulation or sham stimulation along with conventional
therapy. We indexed these as either adequate (independent pain
physicians or investigators who assess the subjective outcome such
as Visual Analogue Scale (VAS) score or quality of life (QoL)); or
inadequate (not performed or similar).
However, as we only included non-randomised controlled trials in
the initial research, we used STROBE (Strengthening the Report-
ing of Observational Studies in Epidemiology), a 22-item check
list (see Table 1), to assess the overall quality of the studies.
Measures of treatment effect
In the original review, we planned to perform all analyses accord-
ing to the ITTprinciple including all randomised participants. For
dichotomous outcomes such as rate of adverse events, we planned
to record percentages with 95% confidence intervals (CI). We in-
tended to calculate the number needed to treat to benefit (NNTB)
from the risk ratio (RR) or risk difference (RD) for RCTs. For
continuous outcomes such as VAS scores, questionnaires or scores
measuring quality of life, we used medians and standard errors
(SEs) or interquartile ranges with CIs to summarise the value in
each group. If different scales had beenused tomeasure continuous
data, we would have used standardised mean differences (SMD).
For this update, we did not perform any meta-analysis or data
synthesis; the results of original analysis were in line with current
Cochrane methodological standards.
Unit of analysis issues
We planned to assess whether groups of individuals were ran-
domised together to the same intervention, whether individuals
undertook more than one intervention and whether multiple in-
vestigators observed the same outcome. For this update, we did
not perform anymeta-analysis or data synthesis; the results of orig-
inal analysis were in line with current Cochrane methodological
standards.
Dealing with missing data
Weplanned to contact the original investigators to request missing
data whenever possible in person, by mail or by phone. If we had
been unable to obtain missing data, we would have imputed the
missing data using mean values.We planned to perform sensitivity
analyses to assess how sensitive results were to reasonable changes
in the assumptions that were made, and we would have addressed
the potential impact of missing data on the findings of the review
in the ’Discussion’ section. We collected and reported dropout
rates in the ’Risk of bias’ table. We used available case analysis
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for extracted data. If the total dropout rate had exceeded 20%,
we planned to use available case analysis and perform subsequent
sensitivity analysis to test the effects of missing data from dropout
participants. If the dropout rate was less than 20%, we planned to
perform ITT analysis.
Assessment of heterogeneity
For the original review, we had planned to use the Chi² test to
assess statistical heterogeneity. If significant heterogeneity would
be found, we planned to re-check that the data were correct and
explore the reason for the heterogeneity. For this update, we did
not perform anymeta-analysis or data synthesis; the results of orig-
inal analysis were in line with current Cochrane methodological
standards.
Assessment of reporting biases
We performed comprehensive searches for studies that met the el-
igibility criteria, including unpublished studies and trial registries
if possible, as authors with financial aid from pharmaceutical com-
panies or authors of studies with negative outcomes tend to se-
lectively report incomplete outcomes. We extracted all important
outcomes of clinical relevance to attempt to eliminate this type of
bias as far as possible.
Data synthesis
In the original study, for the outcome of pain relief, we used a
random-effects to provide a descriptive analysis of extracted data
and no statistical pooling was made (Analysis 1.1; Analysis 2.1).
For this update, we did not perform any meta-analysis or data
synthesis; the results of original analysis were in line with current
Cochrane methodological standards.
Subgroup analysis and investigation of heterogeneity
In the original study,we planned to analyse the associationbetween
different kinds of stimulation apparatus and intervention effects.
As sites of cancer-related pain (lower extremities, trunk or other
sites) or different implantation systemsmay impact on the efficacy
of SCS we would, if possible, have considered the above factors as
parameters when performing subgroup analyses.
For this update, we did not perform any meta-analysis or data
synthesis; the results of original analysis were in line with current
Cochrane methodological standards.
Sensitivity analysis
If we had identified and included RCTs in the original study, we
would have performed sensitivity analysis comparing studies that
had or had not reported: allocation concealment, adequate blind-
ing, or studies without full methodological detail (e.g. published
as abstracts only). For included RCTs, we planned to include all
studies at first, then eliminate one at a time those studies with
moderate or poor quality or those only with abstracts to see if
it altered the results. Finally, we planned to perform the analysis
with data from studies of good methodological quality; thus, the
sensitivity analysis would have been performed in a multiple-step
way. Variation among included studies might cause the issue of
heterogeneity. First, we planned to use the Chi² test to test the
statistical significance of heterogeneity.
As only non-randomised trials were included, we analysed each
trial in a descriptive way.
For this update, we did not perform any meta-analysis or data
synthesis; the results of original analysis were in line with current
Cochrane methodological standards.
R E S U L T S
Description of studies
Results of the search
The initial search strategy yielded 430 articles. By scrutinising ti-
tles and abstracts, we excluded 412 articles due to different scopes
of diseases or different methods of intervention (intrathecal in-
fusion system; oral medication) or aims other than pain control
(spinal cord function monitoring, bladder function restoration or
amelioration of organ metabolism) in the original review. The
remaining 18 trials were reviewed as full manuscripts. No ran-
domised controlled trials (RCTs) were identified; 14 sporadic case
reports were excluded and four uncontrolled longitudinal studies
were included. No additional study was eligible for inclusion in
this updated review. See the flowchart (Figure 3).
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Figure 3. Study flow diagram.
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Included studies
In the original review, comprehensive searching yielded 412 arti-
cles but there were no RCTs that met the inclusion criteria. One
seemingly well-conducted RCT that reported on the use of tran-
scutaneous spinal electro-analgesia was excluded because it did not
meet the definition of spinal cord stimulation (SCS). After consul-
tation with group editors and a group discussion, we modified our
inclusion criteria to include non-randomised controlled trials for
this review. By reading abstracts we identified 18 non-randomised
controlled trials, and after scrutinising these 18 potentially rele-
vant articles, 13 case reports of individual participants plus one
review were also excluded. Four case series studies (Meglio 1989;
Shimoji 1993; Yakovlev 2010; Yakovlev 2011) were included in
the original review. We carried out quality assessment according to
the STROBE statement which aims at assessing methodological
quality of non-randomised controlled trials.
In the research for the update of this review, 39 additional articles
were identified but, after scrutinising the title and abstract, none
of these articles met the eligibility criteria of this review.
Four case series studies (92 participants with cancer) met our
criteria for inclusion in the original review: please see the
’Characteristics of included studies’ table.
Meglio 1989 retrospectively reported on 11 participants with can-
cer from a total of 109 participants who were diagnosed with six
categories of diseases that were eligible for the implantation of
SCS. The rest included participants with vasculopathic pain; lower
back pain; paraplegic pain; deafferentation pain; and post-herpetic
pain. A visual analogue scale (VAS) was used to assess the analgesic
effect of the procedure. Participants with a 50% reduction of pain
intensity were considered to be responders.
Shimoji 1993 reported a large survey of clinical outcomes using
percutaneous, low-frequency SCS to alleviate pain caused by sev-
eral types of diseases including cancer, post-herpetic neuralgia,
spinal trauma, phantom limb pain etc. Visual analogue scales were
used for the evaluation of pain. Percentage of pain relief, long-
term efficacy and adverse events were also reported.
One author published two consecutive articles on treating par-
ticipants with cancer-related pain with SCS. The first article re-
ported on 14 participants who received spinal cord stimulator
placement after surgical or radiological intervention against lung
cancer (Yakovlev 2010). Significant pain relief was calculated as at
least a 50% reduction of the VAS score. The follow-up duration
was 12 months and the safety of the procedure was investigated.
Yakovlev 2011 retrospectively analysed 15 participants with lower
back pain after surgical resection or radiation therapy because of
metastatic disease of adjacent organs. These two trials reported the
percentage of opioid use before and after SCS implantation, pre-
procedure, one month post-implant and 12 months post-implant
using VAS.
Excluded studies
In the initial search, most papers recognised by our searches were
individual case reports on spinal cord stimulation for cancer-re-
lated pain or experimental studies which did not contain clinical
data. After obtaining full texts of potential eligible trials, 14 arti-
cles were excluded. Seven individual case reports of using spinal
cord stimulation to treat cancer-related pain were ruled out be-
cause of limited clinical data obtained from the articles (Cata 2004;
Eisenberg 2002; Hamid 2007; Lee 2009; Nouri 2011; Ting 2007;
Tsubota 2009). Two further case reports were excluded: one in-
cluded two participants (Yakovlev 2008); the other was an indi-
vidual case report (Yakovlev 2009). Three retrospective case series
focused on the effect of SCS on metabolism of, and blood flow to,
cerebral cells; no information on pain control was provided (Clavo
2004; Clavo 2009; Robaina 2007). One review discussing the in-
dications and outcomes of SCS was also excluded (Lee 2006). We
also excluded one article that reported hardware failure of SCS in
benign pain (Rainov 2007). In general, the scarcity of literature
suggests a lack of high-quality clinical trials. Reasons for exclusion
are listed in the ’Characteristics of excluded studies’ table. No ad-
ditional studies were excluded for this update.
Risk of bias in included studies
All included trials were non-randomised trials, so we used the
STROBE 22-item checklist to evaluate the quality of observa-
tional studies (Vandenbroucke 2007). The CONSORT state-
ment, aimed at evaluating allocation, blinding, incomplete out-
come data and reporting bias, could not be used for non-ran-
domised trials (Moher 2001) (Figure 1; Figure 2).
We used the STROBE checklist to assess the overall quality of each
study; this checklist is specially designed for observational studies
(see Table 1). All 22 items were rated as ’yes’, ’no’ or ’unclear’: ’yes’
means that the study was conducted and reported in accordance
with the checklist; ’no’ means that the study was not conducted as
required by the checklist; ’unclear’ means no information related
to each item could be drawn from the article. Two review authors
(Lihua Peng and Ke Wei) independently rated each article and
disagreement was resolved by group discussion. Methodological
quality was generally poor and lacked the components of ’prospec-
tive’ trial design. Of all the 22 items, 5 to 10 items were considered
fulfilled for all included trials (see Table 2). One of the common
issues was the lack of statistical methods to examine or control pos-
sible confounding factors. For all included trials, the enrolment of
participants lacked preset eligibility criteria; the reporting of pri-
mary outcome as pain relief generally lacked subgroup analysis or
intervention interaction (analgesic use and implantation of spinal
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cord stimulation); and all trials lacked a rational explanation of
how the sampling sizes were decided. Therefore we concluded that
all of the included trials were at high risk of bias.
Other potential sources of bias
None known.
Effects of interventions
Heterogeneity existed among all included trials and statistical pool-
ing was not carried out.
Pain Relief
All included trials adopted visual analogue scales (VAS) to evaluate
pain relief. In the earliest article, Meglio 1989 reported on 11 par-
ticipants with cancer pain; three participants reported satisfactory
analgesia (at least a 50% reduction of pain intensity) and received
permanent implantation; the mean level of reduction of pain was
75% in these three participants. One participant lost the thera-
peutic effect after one month of implantation, the two remaining
participants were reported to have experienced a 50% reduction of
pain until death at 2½ and 5 months after implantation (baseline
and post procedure VAS scores were not provided).
Shimoji 1993 retrospectively analysed a total of 454 participants
receiving implantation of SCS for various conditions; subjective
pain relief (at least 50% reduction of original VAS) was observed
in 45 out of 52 participants with cancer-related pain. When the
authors used a 2 x 2 Chi² test to examine the relationship of
background diseases with pain relief, the number of participants
who rated pain relief at more than 50% was significantly larger in
participants with carcinoma/sarcoma than the overall effect (253/
454); yet the study did not provide accurate scores of VAS in this
group of participants and electrodes were withdrawn at the termi-
nal stage in 49 cases of cancer-related pain. Analgesia use during
SCS is also a parameter of clinical efficacy. In 454 participants,
medication was stopped for 52 participants (11%); reduced anal-
gesic use was observed in 263 participants (58%); 323 participants
reported partial to complete pain relief (over 30% of pain reduc-
tion).
Yakovlev reported two consecutive before-and-after case series.
The first study (Yakovlev 2010) enrolled 14 patients with in-
tractable cancer-related chest pain. All participants received per-
manent implantation of an electrode at T3-T4-T5 level. Pain du-
ration before implant was 9 to 23 months (median duration was
16 months). The rate of opioid use before implantation was 100%
(14/14); and 29% (4/14) after the implant with a decreased dose.
Mean value of pre-procedure VAS was 7.43 (standard deviation
(SD) 0.94); one month post implant the VASwas 3.07 (SD 0.62);
12 months post implant VAS was 2.07 (SD 0.83).
The second study (Yakovlev 2011) reported on 15 participants
with intractable cancer-related lower back pain receiving SCS; all
participants had leads inserted at T11 to T12 or T12 to L1 level.
Pain duration before implant was 14 to 26 months (median dura-
tion was 19 months). Rate of opioid use before implant was 100%
(14/14) and 47% (7/15) after implant with a decreased dose.Mean
values of pre-procedure VAS was 7.07 (SD 1.03); one month post
implant VAS was 2.07 (SD 0.9); 12 months post-implant VAS
was 1.87 (SD 0.83). Since no comparison could be made against
other interventional groups, before-and-after comparisons of this
outcome were reported and analysed in narrative forms (Analysis
1.1; Analysis 2.1).
None of the eligible trials reported the other outcomes of health-
related quality of life, physical and functional abilities, or pain-
related anxiety and depression.
Adverse events
Adverse events were reported in participants in two earlier studies
with all diseases eligible for SCS (Meglio 1989; Shimoji 1993).
Meglio 1989 revealed three cases of infection of implantation, four
cases of aseptic meningitis, two cases of rejection of the electrode
leads, three cases of cerebrospinal fluid (CSF) leakage, three cases
of subcutaneous haematoma, two cases of pain at the electrode
sites, three cases of dislodgement of the electrodes, and four cases
of system failure. Other minor side effects included five cases of
headache, five cases of asthenia, five cases of dizziness and six cases
of muscle twitches/contractions in a total of 109 participants (in-
cluding 11 participants with cancer-related pain). Shimoji 1993
reported 6 cases of CSF leakage, 27 cases of infection of implan-
tation,19 cases of pain at the electrode sites, 22 cases of dislodge-
ment of the electrodes and 8 cases of electrode dysfunction in a
total of 454 participants (including 52 participants with cancer-
related pain). In two other recent studies (Yakovlev 2010; Yakovlev
2011), no complications of SCS implantation were reported.
D I S C U S S I O N
Summary of main results
Since the last version of this review, no new studies were found.
In the four before-and-after case series studies included in this
systematic review, clinical efficacy was reported as modest (Meglio
1989), to excellent (Shimoji 1993; Yakovlev 2010; Yakovlev 2011).
Over 80% of participants reported at least a 50% reduction of
pain intensity, more than 50% of participants reported decreased
use of opioid medications. Major complications were infection of
sites of implantation, CSF leakage, pain at the sites of electrodes,
dislodgement of the electrodes and system failure although the
incidence was very low. The follow-up period varied from one
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week to more than one year. However, all these studies were at
high risk of bias.
Overall completeness and applicability of
evidence
In this systematic review, the lack of randomised controlled tri-
als (RCTs) related to this topic left the question of effectiveness
unanswered. Four case series including 92 participants were in-
cluded for descriptive analysis. These four studies varied greatly in
clinical setting, participant characteristics, electrode and stimula-
tor parameters, level of implantation, route of implantation (sub-
arachnoid cavity or epidural cavity) and methods of electrode im-
plantation (laminectomy or percutaneous insertion). Meglio 1989
did not mention the types of cancer and sites of pain and three
out 11 participants with cancer reported excellent pain relief after
implantation. Shimoji 1993 reported outcomes of 52 participants
with cancer-related pain in a cohort of 454 patients. Sites of pain
included head and face, neck and upper extremities, trunk and
lower extremities.Types of cancer and pre-procedure VAS scores
were not provided. Adverse events were reported in participants,
not only with cancer-related pain, but also with chronic pain of
non-cancer origin. In the two later studies the author clarified types
of cancer and sites of pain. One of these described 14 participants
with lung cancer and intractable chest wall pain (Yakovlev 2010).
In this study, pain relief at one-year follow-up was excellent with-
out complication. In another study, 15 participants with cancer-
related lower back pain from metastasis related to colon and anal
cancer, and angiosarcoma of the sacrum were described (Yakovlev
2011). All participants reported significant pain relief (a reduction
of over 50%) that was maintained for at least one year. A major
limitation of the evidence base is that all included studies lacked
preset eligibility of participants and comparison with control.
Quality of the evidence
Only non-controlled case series without interventional compari-
son were available. All studies had small numbers of participants
with cancer and were poorly designed to reach a conclusion about
the comparative efficacy of spinal cord stimulation (SCS) for can-
cer-related pain. Participant attrition, selective reporting and per-
formance bias could have been factors influencing all of the in-
cluded trials. Meglio 1989 was a retrospective analysis of SCS
against chronic pain (cancer-related pain included) in a single in-
stitution without a power calculation. Shimoji 1993 did not per-
form a power calculation nor were the baseline characteristics re-
ported. Yakovlev 2010 and Yakovlev 2011 provided baseline VAS
scores and rate of opioid use; a before-and-after comparison was
made. Lack of randomisation, allocation concealment or blinding
introduced considerable risk of bias. Randomised controlled trials
are still needed to clarify clinical efficacy of SCS in cancer-related
pain. Optimal participant selection, time of implantation and ap-
proaches to minimise its side effects should be analysed.
Potential biases in the review process
All included studies did not comply with the CONSORT state-
ment nor did they meet all essential criteria of the STROBE
checklist. All included trials were before-and-after case series and
no comparison with other interventions could be made. Further-
more, researchers are more likely to report ’positive outcomes’ in
a selected group of participants while leaving ’negative outcomes’
overlooked. In summary, all trials carried with them a great risk of
bias .
Agreements and disagreements with other
studies or reviews
Our review focused on the efficacy and safety of SCS against can-
cer-related pain and no previous published systematic review was
found. Spinal cord stimulation has been utilised for control of
chronic cancer and non-cancer pain for nearly 40 years (Miles
1974; Sweet 1974), but the efficacy of SCS has only been estab-
lished for chronic non-cancer pain, including failed back surgery
syndrome, neuropathic pain, complex regional pain syndrome etc
(Frey 2009; Grabow 2003; Simpson 2009; Taylor 2006). Neuro-
modulation has been given attention to alleviate cancer pain with
encouraging outcomes (Hurlow 2012). Flagg 2012 recommended
that cancer-related pain should be treated at an early stage with an
algorithm integrating SCS. Although all included articles reported
that participants with cancer-related pain may benefit from SCS,
there is no evidence to support or refute the use of SCS in the treat-
ment of pain in patients with cancer (Meglio 1989; Shimoji 1993;
Yakovlev 2010; Yakovlev 2011). The bulk of the literature iden-
tified in this review were individual case reports with greater risk
of bias, and which generally reported positive outcomes. Spinal
cord stimulation should not be compared with ’sham stimulation’
for ethical reasons in patients with cancer; however, the safety and
efficacy of SCS should be compared with other means of pain con-
trol (oral medications; intrathecal drug delivery; transcutaneous
electrostimulation) in patients with cancer.
A U T H O R S ’ C O N C L U S I O N S
Implications for practice
No new relevant studies were identified since the original version
of this review. Current evidence from small, low-quality trials is
insufficient to establish the role of spinal cord stimulation (SCS)
in treating refractory cancer-related pain in comparison with other
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analgesic approaches. Evidence from non-randomised controlled
trials is generally positive and is consistent with a stronger evidence
base in non-cancer pain.
For people with cancer pain
The current evidence is insufficient to establish the role of spinal
cord stimulation in treating cancer-related pain: this technique
may be used after consultingwith a clinician concerning its efficacy
and safety.
For clinicians
The current evidence is insufficient to establish the role of spinal
cord stimulation in treating cancer-related pain. The decision of
clinicians to incorporate this technique into analgesic regimens
should be based on the skills and experience of the clinicians, the
preference of patients and best techniques available.
For policy makers
The current evidence is insufficient to establish the role of spinal
cord stimulation in treating cancer-related pain; further studies are
needed before this technique might be established as an essential
method for pain management in cancer patients.
For funders
The priority of further funding should be given to randomised
controlled trials comparing spinal cord stimulation with other
analgesic methods.
Implications for research
General
Future research should focus on the implantation of SCS in pa-
tients with cancer-related pain at an early stage, and randomised
controlled trials with larger samples are urgently needed to quan-
tify the benefits and harms of this procedure, especially life-quality
improvement and adverse events.
Design
Large, parallel randomised controlled trials, with at least 200 par-
ticipants per arm, comparing spinal cord stimulation with other
analgesic methods are urgently needed.
Measurement (endpoints)
Short-term and long-term analgesic efficacy and adverse events
should be evaluated in future studies.
Other
Economic analysis of spinal cord stimulation for painmanagement
in cancer patient could also be carried out in further research.
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C H A R A C T E R I S T I C S O F S T U D I E S
Characteristics of included studies [ordered by study ID]
Meglio 1989
Methods Part of a retrospective study to analyse 109 patients with chronic pain who underwent
spinal cord stimulation, clinical efficacy was analysed in relation to the aetiology of pain
Participants From 1978 to 1986,109 participants were enrolled: 11 patients with cancer pain; 40
with vasculopathic pain; 19 with lower back pain; 15 with paraplegic pain; 9 with
deafferentation pain; 10 with post-herpetic pain
Interventions Percutaneous placement of the stimulator electrodes or positioned through a small
laminectomy after a test period of 5 to 60 days, two kinds of stimulators were used: the
first was a radiofrequency system; the second was programmable stimulators, which were
programmed with a pulse width of 210 microseconds and a rate of 85 Hz, 64 seconds
on, 1 to 4 minutes off, amplitude was at will to produce comfortable paraesthesia
Outcomes Reduction of visual analogue scale as percentage of analgesia (0% denotes no effect,
100% denotes complete pain relief, a reduction of more than 50% of original pain was
considered as responder); adverse events
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No methods of randomisation were pro-
vided.
Allocation concealment (selection bias) High risk No methods of allocation concealment
were provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No method of blinding were provided.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No methods of blinding were provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information of patient dropout was
provided.
Selective reporting (reporting bias) Low risk This trial reported both analgesic efficacy
and adverse events
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Meglio 1989 (Continued)
Other bias High risk Size of study: high risk of bias (< 50 partic-
ipants per treatment arm). Retrospectively
reported on 11 patients with cancer from
a total of 109 patients who were diagnosed
with six categories of diseases
Shimoji 1993
Methods A survey of clinical results of using percutaneous epidural low-frequency spinal cord
stimulation for chronic pain
Participants Between 1970 and 1991, 454 patients with chronic pain received percutaneous epidural
low-frequency spinal cord stimulation: 52 with carcinoma/sarcoma; 126 with post-her-
petic neuralgia; 189 with causalgia; 12 with spinal trauma; 9 with SMON; 3 with tabes
dorsalis; 8 with phantom pain; 14 with TAO/ASO; 9 with thalamic syndrome; 32 with
other pain
Interventions All patients received implantation of electrodes at sites of pain which connected to
a stimulator that delivered saw-wave pulses (0.5ms in duration ). The frequency of
stimulation was adjustable by the patient at between 1.6 and 8.0 Hz, the intensity being
0.5V to 5.0V. The mode of stimulation was continuous in 9 patients with cancer or
occasional (3 to 12 per day for 20 to 30 min) in 445 patients, depending on patients’
complaints
Outcomes Degree of pain relief as visual analogue scale, 50% of reduction was considered as pain
relief; adverse events
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No methods of randomization were pro-
vided.
Allocation concealment (selection bias) High risk No methods of allocation concealment
were provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No method of blinding were provided.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No methods of blinding were provided.
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Shimoji 1993 (Continued)
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information of patient dropout was
provided.
Selective reporting (reporting bias) Low risk This trial reported both analgesic efficacy
and adverse events
Other bias High risk Size of study: high risk of bias (< 50 partic-
ipants per treatment arm)
Yakovlev 2010
Methods To retrospectively analyse the pain relief outcome of spinal cord stimulation in patients
with cancer-related chest wall pain
Participants From 2005 to 2008,14 patients diagnosed with lung cancer underwent thoracotomy
or lung resection and postoperative radiation therapy, and complained of intractable
chronic chest pain
Interventions 14 patients received percutaneous implantation of permanent leads and stimulators at
T3,T4,T5 after a successful trial of at least 2 days; stimulators were programmed with
a pulse width of 400 to 450 microseconds and a rate of 50 to 60 Hz,amplitude ranged
from 1.5V to 2.3V
Outcomes Rate of opioid use before and after treatment; pre-procedure, 1 month post implant and
12 months post implant visual analogue scale; complication
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No methods of randomisation were pro-
vided.
Allocation concealment (selection bias) High risk No information of allocation concealment
was provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information of blinding was provided.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No information of blinding of outcome as-
sessment was provided
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information of patient dropout was
provided.
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Yakovlev 2010 (Continued)
Selective reporting (reporting bias) Low risk This trial reported both analgesic efficacy
and adverse events
Other bias High risk Size of study: high risk of bias (< 50 partic-
ipants per treatment arm)
Yakovlev 2011
Methods To retrospectively analyse the pain relief of spinal cord stimulation for intractable cancer-
related lower back pain
Participants Between 2005 and 2009,15 patients underwent surgical resections and radiation therapy
because of metastatic disease related to colon, anal cancer, angiosarcoma of the sacrum,
and subsequently complained of intractable chronic low back pain
Interventions 15 patients received percutaneous implantation of permanent leads and stimulators at
T11-12,T12/L1 after successful trial at least 2 days, stimulators were programmed with
a pulse width of 390 to 480 microseconds and a rate of 40 to 60 Hz,amplitude ranged
from 1.4V to 5.2V
Outcomes Rate of opioid use before and after treatment; pre-procedure, 1 month post implant and
12 months post implant visual analogue scale; complications
Notes None
Risk of bias
Bias Authors’ judgement Support for judgement
Random sequence generation (selection
bias)
High risk No methods of randomisation were pro-
vided.
Allocation concealment (selection bias) High risk No information of allocation concealment
was provided.
Blinding of participants and personnel
(performance bias)
All outcomes
High risk No information of blinding was provided.
Blinding of outcome assessment (detection
bias)
All outcomes
High risk No information of blinding was provided.
Incomplete outcome data (attrition bias)
All outcomes
Unclear risk No information of patient dropout was
provided.
Selective reporting (reporting bias) Low risk This trial reported both analgesic efficacy
and adverse events
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Yakovlev 2011 (Continued)
Other bias High risk Size of study: high risk of bias (< 50 partic-
ipants per treatment arm)
ASO: arteriosclerosis obliterans
SMON: subacute myelo-optico-neuropathy
TAO: thromboangiitis obliterans
Characteristics of excluded studies [ordered by study ID]
Study Reason for exclusion
Cata 2004 Individual case report.
Clavo 2004 Outcomes not related to the topic of systematic review.
Clavo 2009 Outcomes not related to the topic of systematic review.
Eisenberg 2002 Individual case report.
Hamid 2007 Individual case report.
Lee 2006 Review article of SCS.
Lee 2009 Individual case report.
Nouri 2011 Individual case report.
Rainov 2007 Outcomes not related to the topic of review.
Robaina 2007 Individual case report.
Ting 2007 Individual case report.
Tsubota 2009 Individual case report.
Yakovlev 2008 Case report including only 2 patients.
Yakovlev 2009 Individual case report.
SCS: spinal cord stimulation
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D A T A A N D A N A L Y S E S
Comparison 1. Pain Intensity after SCS implantation
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain intensity---Visual Analogue
Scale
2 58 Mean Difference (IV, Random, 95% CI) 4.38 [3.93, 4.83]
Comparison 2. Pain intensity---1 month after SCS versus 12 months after SCS
Outcome or subgroup title
No. of
studies
No. of
participants Statistical method Effect size
1 Pain Intensity---Visual Analogue
Scale
2 58 Mean Difference (IV, Fixed, 95% CI) 0.91 [0.50, 1.32]
Analysis 1.1. Comparison 1 Pain Intensity after SCS implantation, Outcome 1 Pain intensity---Visual
Analogue Scale.
Review: Spinal cord stimulation for cancer-related pain in adults
Comparison: 1 Pain Intensity after SCS implantation
Outcome: 1 Pain intensity—Visual Analogue Scale
Study or subgroup
before scs
implanta-
tion after scs implantation
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Random,95% CI IV,Random,95% CI
Yakovlev 2010 14 7.43 (0.94) 14 3.07 (0.62) 57.9 % 4.36 [ 3.77, 4.95 ]
Yakovlev 2011 15 7.07 (1.03) 15 2.67 (0.9) 42.1 % 4.40 [ 3.71, 5.09 ]
Total (95% CI) 29 29 100.0 % 4.38 [ 3.93, 4.83 ]
Heterogeneity: Tau2 = 0.0; Chi2 = 0.01, df = 1 (P = 0.93); I2 =0.0%
Test for overall effect: Z = 19.11 (P < 0.00001)
Test for subgroup differences: Not applicable
-10 -5 0 5 10
Favours no scs Favours scs implantation
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Analysis 2.1. Comparison 2 Pain intensity---1 month after SCS versus 12 months after SCS, Outcome 1
Pain Intensity---Visual Analogue Scale.
Review: Spinal cord stimulation for cancer-related pain in adults
Comparison: 2 Pain intensity—1 month after SCS versus 12 months after SCS
Outcome: 1 Pain Intensity—Visual Analogue Scale
Study or subgroup 1 month after scs 12 months after scs
Mean
Difference Weight
Mean
Difference
N Mean(SD) N Mean(SD) IV,Fixed,95% CI IV,Fixed,95% CI
Yakovlev 2010 14 3.07 (0.62) 14 2.07 (0.83) 56.6 % 1.00 [ 0.46, 1.54 ]
Yakovlev 2011 15 2.67 (0.9) 15 1.87 (0.83) 43.4 % 0.80 [ 0.18, 1.42 ]
Total (95% CI) 29 29 100.0 % 0.91 [ 0.50, 1.32 ]
Heterogeneity: Chi2 = 0.23, df = 1 (P = 0.63); I2 =0.0%
Test for overall effect: Z = 4.38 (P = 0.000012)
Test for subgroup differences: Not applicable
-4 -2 0 2 4
Favours1month after scs Favours12months after scs
A D D I T I O N A L T A B L E S
Table 1. STROBE checklist
Structure Item Recommendation
Title and abstract 1 Indicate the study’s design with a commonly used term in the title or the abstract; provide in
the abstract an informative and balanced summary of what was done and what was found
Introduction
Background/rationale 2 Explain the scientific background and rationale for the investigation being reported
Objectives 3 State specific objectives, including any prespecified hypotheses
Methods
Study design 4 Present key elements of study design early in the paper.
Setting 5 Describe the setting, locations, and relevant dates, including periods of recruitment, exposure,
follow-up, and data collection
Participants 6 Give the eligibility criteria, and the sources and methods of selection of participants
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Table 1. STROBE checklist (Continued)
Variables 7 Clearly define all outcomes, exposures, predictors, potential confounders, and effect modifiers.
Give diagnostic criteria, if applicable
Data sources/
measurement
8 For each variable of interest, give sources of data and details of methods of assessment (mea-
surement). Describe comparability of assessment methods if there is more than one group
Bias 9 Describe any efforts to address potential sources of bias.
Study size 10 Explain how the study size was arrived at.
Quantitative variables 11 Explain how quantitative variables were handled in the analyses. If applicable, describe which
groupings were chosen and why
Statistical methods 12 (a) Describe all statistical methods, including those used to control for confounding.
(b) Describe any methods used to examine subgroups and interactions.
(c) Explain how missing data were addressed.
(d) If applicable, describe analytical methods taking account of sampling strategy
Results
Participants 13 (a) Report numbers of individuals at each stage of study-e.g. numbers potentially eligible,
examined for eligibility, confirmed eligible, included in the study, completing follow-up, and
analysed.
(b) Give reasons for non-participation at each stage.
(c) Consider use of a flow diagram.
Descriptive
data
14 (a)Give characteristics of study participants (e.g. demographic, clinical, social) and information
on exposures and potential confounders.
(b) Indicate number of participants with missing data for each variable of interest
Outcome data 15 Report numbers of outcome events or summary measures.
Main results 16 If relevant, consider translating estimates of relative risk into absolute risk for a meaningful
time period
Other analyses 17 Report other analyses done-e.g. analyses of subgroups and interactions, and sensitivity analyses
Discussion
Key results 18 Summarise key results with reference to study objectives.
Limitations 19 Discuss limitations of the study, taking into account sources of potential bias or imprecision.
Discuss both direction and magnitude of any potential bias.
Interpretation 20 Give a cautious overall interpretation of results considering objectives, limitations, multiplicity
of analyses, results from similar studies, and other relevant evidence
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Table 1. STROBE checklist (Continued)
Generalisability 21 Discuss the generalisability (external validity) of the study results
Other information
Funding 22 Give the source of funding and the role of the funders for the present study and, if applicable,
for the original study on which the present article is based
Table 2. Result of STOBE Checklist
Item No. Meglio 1989 Shimoji 1993 Yakovlev 2010 Yakovlev 2011
1 Y Y Y Y
2 N Y Y Y
3 N Y Y Y
4 N N N N
5 N N Y Y
6 N N N N
7 N N N N
8 N N N Y
9 N N N N
10 N N N N
11 Y Y Y Y
12 N N N N
13 N N N N
14 N N N N
15 Y Y Y Y
16 N N N N
17 N N N N
18 Y Y Y Y
19 N N N N
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Table 2. Result of STOBE Checklist (Continued)
20 Y Y Y Y
21 Y Y Y Y
22 N N Y Y
Y:Yes; N:No; U:Unlear
A P P E N D I C E S
Appendix 1. Search strategies
CENTRAL (The Cochrane Library)
MESH DESCRIPTOR Neoplasms EXPLODE ALL TREES
(cancer* or carcino* or tumour* or tumor* or neoplas* or malig*):TI,AB,KY
#1 OR #2
MESH DESCRIPTOR Pain EXPLODE ALL TREES
pain*:TI,AB,KY
#4 OR #5
MESH DESCRIPTOR Electric Stimulation Therapy EXPLODE ALL TREES
MESH DESCRIPTOR Spinal Cord EXPLODE ALL TREES
(spinal cord stimulation*):TI,AB,KY
SCS:TI,AB,KY
#7 OR #8 OR #9 OR #10
#3 AND #6 AND #11
11/07/2012 TO 30/10/2014:DL
#12 AND #13
MEDLINE (OVID)
1 (cancer$ or carcino$ or tumour$ or tumor$ or neoplas$ or malig$).tw.
2 exp Neoplasms/
3 1 or 2
4 exp pain/
5 pain$.tw.
6 4 or 5
7 exp Electric Stimulation Therapy/
8 exp Spinal Cord/
9 spinal cord stimulation$.tw.
10 scs.tw.
11 dorsal column stimulation.tw.
12 7 or 8 or 9 or 10 or 11
13 3 and 6 and 12
EMBASE (OVID)
1 (cancer$ or carcino$ or tumour$ or tumor$ or neoplas$ or malig$).tw.
2 exp Neoplasm/
3 1 or 2
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4 exp pain/
5 pain$.tw.
6 4 or 5
7 exp Electrostimulation Therapy/
8 exp Spinal Cord/
9 spinal cord stimulation$.tw.
10 scs.tw.
11 dorsal column stimulation.tw.
12 7 or 8 or 9 or 10 or 11
13 3 and 6 and 12
CMB(Chinese Biomedical Database )
1 ( $ or $ or $ or $).tw.
2 exp /
3 1 or 2
4 exp /
5 $.tw.
6 4 or 5
7 exp /
8 exp /
9 $.tw.
10 .tw.
11 7 or 8 or 9 or 10
12 3 and 6 and 11
WH A T ’ S N E W
Last assessed as up-to-date: 6 October 2014.
Date Event Description
6 February 2015 New citation required but conclusions have not
changed
No new studies were identified for inclusion in this
update and the conclusions remain unchanged accord-
ingly. Risk of bias summary tables added
27 December 2014 New search has been performed Search updated in October 2014.
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C O N T R I B U T I O N S O F A U T H O R S
Lihua Peng wrote the protocol draft, updated literature and wrote the updated review.
Michael Bennett modified the protocol and guided the data analysis in the original review.
Lihua Peng conceived the idea for this review and gave some suggestions on the protocol.
Su Min and Ke Wei did the search and extracted the data for the original review and the study selection of the updated review.
Ke Wei carried out the analysis for the full review.
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Internal sources
• Department of Anaesthesia and Pain Medicine, Chongqing Medical University, China.
External sources
• Cochrane Pain, Palliative and Supportive Care Review Group, UK.
D I F F E R E N C E S B E TW E E N P R O T O C O L A N D R E V I E W
Where randomised trial evidence is desired but unlikely to be available, eligibility criteria defines that non-randomised trials would
only be included where randomised trials are found not to be available and non-randomised trials will be appraised with commonly
used checklists for methodological quality (Reeves 2011).
We intended to include randomised controlled trials (RCTs); however, we did not find any such trials. For the previous version of
the review, after consultation with the Pain, Palliative and Supportive Care Review Group group editors and a group discussion, we
modified our inclusion criteria to include non-randomised controlled trials for this review.
We added Cochrane ’Risk of bias’ tool and summary tables in the updated version of this review.
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I N D E X T E R M S
Medical Subject Headings (MeSH)
∗Spinal Cord Stimulation; Analgesics, Opioid [administration & dosage]; Checklist; Neoplasms [∗complications]; Pain [∗etiology];
Pain Management [adverse effects; ∗methods]; Pain Measurement
MeSH check words
Adult; Humans
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